Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 122.94M P/E - EPS this Y -3.30% Ern Qtrly Grth -
Income -19.9M Forward P/E -4.91 EPS next Y -22.60% 50D Avg Chg -7.00%
Sales - PEG -0.23 EPS past 5Y - 200D Avg Chg 61.00%
Dividend N/A Price/Book 3.17 EPS next 5Y 30.00% 52W High Chg -32.00%
Recommedations 1.70 Quick Ratio 17.63 Shares Outstanding 42.75M 52W Low Chg 189.00%
Insider Own 26.23% ROA -23.54% Shares Float 26.16M Beta 1.48
Inst Own 30.42% ROE -35.18% Shares Shorted/Prior 138.44K/142.04K Price 3.24
Gross Margin - Profit Margin - Avg. Volume 164,891 Target Price 7.00
Oper. Margin - Earnings Date Nov 11 Volume 47,437 Change -0.61%
About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

DiaMedica Therapeutics Inc. News
11/16/24 We're Not Very Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Rate
11/15/24 Q3 2024 DiaMedica Therapeutics Inc Earnings Call
11/13/24 DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results
11/13/24 DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia
11/12/24 DiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select Conference
11/06/24 DiaMedica Therapeutics to Provide a Business Update and Report Third Quarter 2024 Financial Results November 14, 2024
10/14/24 Best Momentum Stocks to Buy for October 14th
10/10/24 DiaMedica gets SAHPRA approval for Phase II preeclampsia treatment trial
10/09/24 DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia
10/08/24 DiaMedica Therapeutics Insiders Placed Bullish Bets Worth US$9.05m
09/04/24 DiaMedica Therapeutics Upcoming Conference Participation
09/03/24 Is Atossa Genetics (ATOS) Outperforming Other Medical Stocks This Year?
08/07/24 DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial Results
08/01/24 Are Medical Stocks Lagging DiaMedica Therapeutics (DMAC) This Year?
08/01/24 DiaMedica Therapeutics to Provide a Business Update and Report Second Quarter 2024 Financial Results August 8, 2024
07/11/24 DiaMedica Therapeutics Inc.'s (NASDAQ:DMAC) largest shareholders are individual investors with 50% ownership, insiders own 39%
07/11/24 DiaMedica Therapeutics Releases Preeclampsia White Paper and Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia
07/01/24 DiaMedica Therapeutics Announces Closing of $11.8 Million Private Placement
06/26/24 DiaMedica Therapeutics Announces $11.8 Million Private Placement
06/26/24 DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia
DMAC Chatroom

User Image ThriftyMan Posted - 14 hours ago

$DMAC Is that volume for real? That is wild.

User Image Sukitt Posted - 15 hours ago

$DMAC 1 million+ volume out the gate. Strange. Probably nothing.

User Image d_risk Posted - 1 week ago

$DMAC - DiaMedica Therapeutics Inc. Common Stock - 10Q - Updated Risk Factors New risk factors: DM199 program expansion into PE faces timing, regulatory, cost, and enrollment risks; regulatory approval in South Africa; potential financial impact from adverse trial data. #Risk @Dismedica https://d-risk.ai/DMAC/10-Q/2024-11-13

User Image justiceforb_85 Posted - 1 week ago

$DMAC do we have any data for efficacy of rinvecalinase in either stroke or pre-eclampsia?

User Image swingingtech Posted - 1 month ago

$IAG $DMAC $HIVE https://wallstreetwaves.com/best-momentum-stocks-to-buy-for-october-14th/

User Image briefingcom Posted - 1 month ago

$DMAC: DiaMedica Therapeutics announces regulatory approval has been received to initiate a Phase 2 clinical trial with DM199, its proprietary recombinant serine protease, for the treatment of preeclampsia https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20241009082819DMAC&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

User Image Doozio Posted - 1 month ago

$DMAC da FUTUre of 🧠⏰ is NOW during 🧠⏰♾️

User Image kshonstocks Posted - 1 month ago

$DMAC hitting scan, like pattern

User Image IN0V8 Posted - 1 month ago

$DMAC Opportunity H.C. Wainwright initiates coverage with buy rating

User Image Sukitt Posted - 1 month ago

$DMAC

User Image eneub87 Posted - 1 month ago

$DMAC Mo money making this coming week.

User Image WineauxInBordeaux Posted - 2 months ago

@LFB1374 don’t RELY on my recommendation. Due your own DD but $DMAC is one to watch. I also like $LPTH. It won’t make you rich but it could double or triple if $LMT wins DOD contracts for nextgen stinger missile systems, to replace all those we sent to the Ukraine.

User Image moneyshop Posted - 2 months ago

$ABT $LLY $GILD Here is a bio Co that has break thru treatments for strokes, 2 billionaires who were former executives/founders of EQT private equity firm bought millions worth of $DMAC stock in the last capital raise. they must see a big opportunity. diamedica.com

User Image moneyshop Posted - 2 months ago

$AMGN Here is a bio Co that has break thru treatments for strokes, 2 billionaires who were former executives/founders of EQT private equity firm bought millions worth of $DMAC stock in the last capital raise. they must see a big opportunity. https://www.diamedica.com/

User Image moneyshop Posted - 2 months ago

$DMAC has a drug that saves stroke victims from brain damage if administered within 2 hours. This is a huge breakthru stock should go ballistic.

User Image Sicksir Posted - 2 months ago

$DMAC Break $5!

User Image RJRNAB Posted - 2 months ago

$DMAC volume picking up for some reason

User Image PenkeTrading Posted - 2 months ago

I found you an Overbought RSI (Relative Strength Index) on the daily chart of DiaMedica Therapeutics Inc. Is that bullish or bearish? $DMAC #DMAC #nasdaq #tradingsignals #technicalanalysis

User Image Viter Posted - 2 months ago

$DMAC As expected...

User Image Sicksir Posted - 2 months ago

$DMAC someone wants it

User Image Danger_Will_Robinson Posted - 2 months ago

$DMAC what are the odds there’s another financing …. Seems to happen every time stock makes move higher … conference presentation trail under way for this fall it looks like

User Image Viter Posted - 2 months ago

$DMAC soon or later we will break this wall at 4$

User Image Sukitt Posted - 08/29/24

$DMAC

User Image kshonstocks Posted - 2 months ago

$DMAC 92 A https://research.investors.com/stock-quotes/nasdaq-diamedica-therapeutics-dmac.htm hitting scan

User Image johnbloom Posted - 3 months ago

$DMAC still a mystery as to why 2 billionaires who were former executives/founders of EQT private equity firm would buy millions worth of $DMAC stock in the last capital raise. they must see a big opportunity with this company. very very interesting

User Image nailman Posted - 3 months ago

$DMAC why is the stock up? They just raised money again and there’s years of work to get anywhere with this stock. I may be wrong but it’s just seems like a pattern to me. Nothing great about the news or the company yet.

User Image LongtermZ94 Posted - 3 months ago

Analyst thoughts on $DMAC $DMAC reported 2Q24 with EPS of ($0.13), beating both our estimate and Street consensus of ($0.16)E. On the P2/3 ReMEDy2 program, we are encouraged by the progress in site activations and high interest from sites and potential investigators, and are pleased to see 1Q25 interim enrollment timeline reiterated. However, we maintain our cautious optimism due to historical stroke trial patient enrollment challenges. On the preeclampsia program, we remind investors that we believe DM199's MOA and promising preclinical data provide a strong rationale for further clinical development. P2 still expected to initiate in 4Q24 with topline in 1H25. As DMAC continues to make strides in both its programs (only valuing AIS at this time), we reiterate our Outperform/$6 PT. $DMAC $QQQ

User Image Tjcmd Posted - 3 months ago

$DMAC next catalyst?

User Image Cats_and_Roses Posted - 3 months ago

$DMAC Nothing to see here until some time in Q1 2025, unless the next quarterly update says otherwise

User Image Tjcmd Posted - 3 months ago

$DMAC some clown posting this on SA

Analyst Ratings
Oppenheimer Outperform Aug 16, 24
Craig-Hallum Buy Mar 21, 24
Oppenheimer Outperform Mar 21, 24
Oppenheimer Outperform Jun 22, 23
Lake Street Buy Jul 7, 22
Craig-Hallum Buy Jul 7, 22
Oppenheimer Perform Jul 7, 22
Roth Capital Buy Jun 30, 21
Oppenheimer Outperform Apr 8, 21
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Giuffre Randall Michael Director Director Jun 23 Buy 3.91 65,000 254,150 360,355 06/26/23
Pauls Dietrich John President and CEO President and CEO Jun 23 Buy 3.91 12,787 49,997 68,591 06/26/23
Wambeke David J. Chief Business Offic.. Chief Business Officer Apr 10 Buy 1.6 468,750 750,000 468,750 04/11/23
Giuffre Randall Michael Director Director Dec 06 Buy 1.38 24,874 34,326 203,146 12/08/22
Giuffre Randall Michael Director Director Nov 29 Buy 1.19 67,228 80,001 177,453 12/01/22
Pauls Dietrich John President and CEO President and CEO Nov 16 Buy 1.21 20,000 24,200 55,804 11/16/22
Von Koch Thomas 10% Owner 10% Owner Jul 08 Buy 1.3266 207,974 275,898 2,855,827 07/21/22